HIV Scientific Papers
Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial.
2017
PLoS One.
Clemmons DR, Miller S, Mamputu J-C, et al.
12(6):e0179538.
Efficacy and safety of ibalizumab (IBA) in a Phase 3 study of heavily treatment-experienced patients with multi-drug resistant (MDR) HIV-1 infection [abstract].
2016
Open Forum Infect Dis.
Lalezari J, Fessel J, Schrader S, et al.
3(suppl 1):LB-6. Proceedings of IDWeek, 2016.
Efficacy and safety of ibalizumab (IBA) in a Phase 3 study of heavily treatment-experienced patients with multi-drug resistant (MDR) HIV-1 infection.
2016
Lalezari J.
Oral presentation #LB-6 at: IDWeek; Oct 26-30, 2016; New Orleans, Louisiana, USA.
Predictors of treatment response to tesamorelin, a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat.
2015
PLoS One.
Mangili A, Falutz J, Mamputu J-C, et al.
10(10):e0140358.
Population pharmacokinetic and pharmacodynamic analysis of tesamorelin in HIV-infected patients and healthy subjects.
2015
J Pharmacokinet Pharmacodyn.
González-Sales M, Barrière O, Tremblay PO, et al.
42(3):287-299.